NewAmsterdam Pharma rises on positive data in cholesterol-lowering treatment trial

NewAmsterdam Pharma

17/01/2023 15:26

** U.S.-listed shares of Netherlands based NewAmsterdam
Pharma Company NV  NAMS.O  up 3.3% at $10.6
    ** Co says its experimental oral inhibitor, obicetrapib, met
the primary goal in a mid-stage trial 
    ** Drug showed a statistically significant reduction in
low-density lipoprotein cholesterol (LDL-C) or "bad" cholesterol
    ** The trial tested co's therapy with in combination with
high cholesterol treatment medicine ezetimibe in statin therapy
treatment for patients who require additional lowering of LDL-C 
    ** Co says it is selecting a fixed dose of the combination
tablet to be tested in a bioequivalence trial and a late-stage
safety and efficacy trial 
    ** NAMS anticipates sharing full data from the mid-stage
trial in a forthcoming publication or in a presentation at an
upcoming medical meeting 
    ** In 2022, NAMS stock was up 11.8% 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))